Last reviewed · How we verify
NCT03844932
A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase 2 trial testing ST-0529 in Colitis, Ulcerative in 235 participants. Terminated before completion.
14 April 2021
Quick facts
| Lead sponsor | Sublimity Therapeutics Holdco Limited |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 235 |
| Start date | 24 January 2019 |
| Primary completion | 14 April 2021 |
| Estimated completion | 14 April 2021 |
| Sites | 89 locations across France, Italy, Russia, Ukraine, Serbia, Ireland, United Kingdom, Germany |
Drugs / interventions tested
- ST-0529 — full drug profile →
Conditions studied
- Colitis, Ulcerative — all drugs for Colitis, Ulcerative →
Sponsor
Sublimity Therapeutics Holdco Limited — full company profile →
Who can join
Adults 18 to 75, any sex, with Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark<b>Special Reporting
· 2019 · cited 8× · PMID 31632213
Verify or expand the search:
- PubMed search for NCT03844932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colitis, Ulcerative
Currently open trials in the same condition.
- NCT07302360 — A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis · recruiting
- NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
- NCT07196748 — A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Col · Phase 3 · recruiting
- NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
- NCT06651281 — Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Coli · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03844932 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sublimity Therapeutics Holdco Limited
- Last refreshed: 7 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03844932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing